.svg)
As the medical device clinical trial market is rapidly growing, so are the opportunities to augment traditional study designs with virtual trial sites and DCT solutions. However, there are a number of misconceptions about online patient recruitment, enrollment, and participation. In this session at SCOPE 2022, Jane Myles, VP of Clinical Trial Innovation at Curebase, busts seven of these “virtual site myths” using first-hand data from a gastroenterology digital therapeutics trial, and shares never-before-seen patient experience data.
About Curebase
Curebase is reinventing decentralized clinical trials to help the vast majority of potential patients that currently cannot access clinical research. Our vision is that any patient, no matter where they are located, should be able to participate in clinical trials at home and with their own doctors. This is made possible through a unique suite of tools Curebase’s has designed to engage patients in clinical trials across all settings, be it at home, at their local clinic, or other places in their community.
This starts with Curebase’s leading decentralized clinical trial software platform that is an all-in-one, purpose built eClinical software system, with every tool needed to manage and collect data for decentralized clinical trials. This includes ePRO, eCOA, eConsent, Telemedicine, and much more. Curebase also offers a virtual research site, complete with virtual investigators, research coordinators, mobile nursing, and other healthcare staff that administer care to patients where convenient for them, just like any other research site, but with the ability to stand up anywhere and with greater patient convenience and reach. Notably, Curebase is the pioneer of the “BYOP” or Bring Your Own Physician model, allowing patients to use their own doctors to participate in clinical trials.
We are reinventing a $45B market, enabling drug and device companies to increase the volume, quality, and speed of data collection regardless of patients’ physical location. COVID-19 tailwinds have created massive demand for telemedicine and home-based trials, with two new FDA guidance letters and industry-wide adoption of remote remote research that will only accelerate in the years to come. You can learn more about Curebase and our next stage of growth in Crunchbase, Fierce Biotech, and MedCity News!
Interested in staying up to date with Curebase's latest developments in the decentralized clinical trial space? Get regular updates on news, webinars, blogs and more by subscribing here.
As the medical device clinical trial market is rapidly growing, so are the opportunities to augment traditional study designs with virtual trial sites and DCT solutions. However, there are a number of misconceptions about online patient recruitment, enrollment, and participation. In this session at SCOPE 2022, Jane Myles, VP of Clinical Trial Innovation at Curebase, busts seven of these “virtual site myths” using first-hand data from a gastroenterology digital therapeutics trial, and shares never-before-seen patient experience data.
About Curebase
Curebase is reinventing decentralized clinical trials to help the vast majority of potential patients that currently cannot access clinical research. Our vision is that any patient, no matter where they are located, should be able to participate in clinical trials at home and with their own doctors. This is made possible through a unique suite of tools Curebase’s has designed to engage patients in clinical trials across all settings, be it at home, at their local clinic, or other places in their community.
This starts with Curebase’s leading decentralized clinical trial software platform that is an all-in-one, purpose built eClinical software system, with every tool needed to manage and collect data for decentralized clinical trials. This includes ePRO, eCOA, eConsent, Telemedicine, and much more. Curebase also offers a virtual research site, complete with virtual investigators, research coordinators, mobile nursing, and other healthcare staff that administer care to patients where convenient for them, just like any other research site, but with the ability to stand up anywhere and with greater patient convenience and reach. Notably, Curebase is the pioneer of the “BYOP” or Bring Your Own Physician model, allowing patients to use their own doctors to participate in clinical trials.
We are reinventing a $45B market, enabling drug and device companies to increase the volume, quality, and speed of data collection regardless of patients’ physical location. COVID-19 tailwinds have created massive demand for telemedicine and home-based trials, with two new FDA guidance letters and industry-wide adoption of remote remote research that will only accelerate in the years to come. You can learn more about Curebase and our next stage of growth in Crunchbase, Fierce Biotech, and MedCity News!
As the medical device clinical trial market is rapidly growing, so are the opportunities to augment traditional study designs with virtual trial sites and DCT solutions. However, there are a number of misconceptions about online patient recruitment, enrollment, and participation. In this session at SCOPE 2022, Jane Myles, VP of Clinical Trial Innovation at Curebase, busts seven of these “virtual site myths” using first-hand data from a gastroenterology digital therapeutics trial, and shares never-before-seen patient experience data.
About Curebase
Curebase is reinventing decentralized clinical trials to help the vast majority of potential patients that currently cannot access clinical research. Our vision is that any patient, no matter where they are located, should be able to participate in clinical trials at home and with their own doctors. This is made possible through a unique suite of tools Curebase’s has designed to engage patients in clinical trials across all settings, be it at home, at their local clinic, or other places in their community.
This starts with Curebase’s leading decentralized clinical trial software platform that is an all-in-one, purpose built eClinical software system, with every tool needed to manage and collect data for decentralized clinical trials. This includes ePRO, eCOA, eConsent, Telemedicine, and much more. Curebase also offers a virtual research site, complete with virtual investigators, research coordinators, mobile nursing, and other healthcare staff that administer care to patients where convenient for them, just like any other research site, but with the ability to stand up anywhere and with greater patient convenience and reach. Notably, Curebase is the pioneer of the “BYOP” or Bring Your Own Physician model, allowing patients to use their own doctors to participate in clinical trials.
We are reinventing a $45B market, enabling drug and device companies to increase the volume, quality, and speed of data collection regardless of patients’ physical location. COVID-19 tailwinds have created massive demand for telemedicine and home-based trials, with two new FDA guidance letters and industry-wide adoption of remote remote research that will only accelerate in the years to come. You can learn more about Curebase and our next stage of growth in Crunchbase, Fierce Biotech, and MedCity News!
.svg)
We'd love to hear from you, whether a Sponsor interested in running a study with us, a provider looking to get involved in clinical research, or patients interested in our studies. Fill out your information below and one of our team members will be in touch.
Interested in staying up to date with Curebase's latest developments in the decentralized clinical trial space? Get regular updates on news, webinars, blogs and more by subscribing here.
%201.svg){kind=logo}
